CareDx, Inc. (CDNA) director sells 16,000 shares in planned trade

Rhea-AI Filing Summary

CareDx, Inc. director Christine Cournoyer sold 16,000 shares of common stock on 2026-08-04 in open-market transactions under a Rule 10b5-1 trading plan. The weighted average sale price was $46.9358 per share, within a $46.25–$47.2250 range, leaving her with 42,943 shares held directly.

Insider Trade Summary 10b5-1

Net Seller: 16,000 shares

Net Sell 1 txn

Insider COURNOYER CHRISTINE

Role Director

Sold 16,000 shs ($751K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	16,000	$46.9358	$751K

Holdings After Transaction: Common Stock — 42,943 shares (Direct)

Footnotes (1)

1. F1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.2250 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 16,000 shares Weighted average sale price: $46.9358 per share Sale price range: $46.25–$47.2250 per share +1 more

4 metrics

Shares sold 16,000 shares Common Stock sale on 2026-08-04

Weighted average sale price $46.9358 per share Weighted average price for 16,000-share sale

Sale price range $46.25–$47.2250 per share Multiple sale transactions executed within this range

Shares owned after sale 42,943 shares Direct ownership following the reported transaction

Key Terms

Rule 10b5-1, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 regulatory

"Transactions are designated under a Rule 10b5-1 trading plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction market

"Transaction code description: Sale in open market or private transaction."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/06/2026 - 04:11 PM Accepted by SEC EDGAR 08/06/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What insider transaction did CareDx (CDNA) report in this Form 4?

CareDx reported that director Christine Cournoyer sold 16,000 shares of common stock on 2026-08-04. The transaction was a sale in the open market or private transaction and is associated with a Rule 10b5-1 trading plan.

How many CareDx (CDNA) shares did Christine Cournoyer sell and at what average price?

Christine Cournoyer sold 16,000 shares of CareDx common stock at a weighted average price of $46.9358 per share. The sale was executed through multiple transactions, all recorded for the same trade date of 2026-08-04.

What was the price range for the CareDx (CDNA) shares sold by Christine Cournoyer?

The 16,000 CareDx shares were sold at prices ranging from $46.25 to $47.2250 per share. The reported transaction price is a weighted average calculated across these multiple sale executions.

How many CareDx (CDNA) shares does Christine Cournoyer own after this sale?

After completing the reported sale, Christine Cournoyer directly owns 42,943 shares of CareDx common stock. This figure reflects her direct beneficial ownership immediately following the 16,000-share disposition on 2026-08-04.

Was the CareDx (CDNA) insider sale made under a Rule 10b5-1 trading plan?

Yes. The transaction is designated as being under a Rule 10b5-1 trading plan, as indicated by the checked Rule 10b5-1 box. Such pre-arranged plans automate trades according to preset instructions, reducing the role of day-to-day discretion in timing.

Is the CareDx (CDNA) sale categorized as a market purchase or sale transaction?

The transaction is coded as “S”, meaning a sale in an open market or private transaction. This code confirms the activity was a disposition of shares rather than an acquisition or option exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COURNOYER CHRISTINE

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD, 4TH FLOOR

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/04/2026		S		16,000	D	$46.9358(1)	42,943	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.2250 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Jeffrey Adam Novack, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)